^
    1d
    CD45BE-HSPC + CART-45 Cells (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, University of Pennsylvania
    New P1 trial
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    3d
    Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Recruiting, ModeX Therapeutics, An OPKO Health Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    4d
    Combined oral PI3Kδ inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 trial. (PubMed, Leuk Lymphoma)
    With a median follow-up time of 13.0 months, median duration of response (DOR), progression-free survival, and overall survival (OS) were not reached. In conclusion, linperlisib plus chidamide demonstrated a favorable safety profile and encouraging preliminary efficacy in r/r PTCL.
    P1 data • Journal
    |
    PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
    |
    Epidaza (chidamide) • Itari (linperlisib)
    4d
    CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Stanford University
    New P1 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC rearrangement + BCL2 rearrangement
    |
    rapcabtagene autoleucel (YTB323)
    4d
    A rare diffuse follicular lymphoma with TP53 mutation and copy-neutral loss of heterozygosity at 1p36: insights into diagnosis, disease progression, and literature review. (PubMed, J Hematop)
     These findings underscore the importance of comprehensive molecular testing, such as NGS and CMA, to refine prognostic assessment and guide personalized treatment strategies for this rare lymphoma variant.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • TNFRSF14 (TNF Receptor Superfamily Member 14)
    |
    TP53 mutation
    4d
    Causal association between oxidative stress and lymphomas: A two-sample Mendelian randomization study. (PubMed, Int J Biol Markers)
    Heterogeneity was noted for uric acid and DLBCL, but no pleiotropy was detected; after outlier removal, the association with uric acid was non-significant.ConclusionsThe findings suggest causal relationships between oxidative stress markers and lymphoma risk, notably MPO and GPX with follicular lymphoma, and inverse associations for GST and CAT with different lymphoma types. Limitations include heterogeneity for some markers, requiring further validation.
    Journal
    |
    CAT (Catalase) • MPO (Myeloperoxidase)
    4d
    GP-1: Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma (clinicaltrials.gov)
    P1/2, N=53, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Gazyva (obinutuzumab) • pomalidomide
    5d
    Born with two faces: sequential DLBCL, NOS and TFHL-AI with TET2 mutation - a case report. (PubMed, Front Immunol)
    He achieved complete remission following six cycles of R-CHOP chemotherapy (rituximab, cyclophosphamide, vindesine, liposomal doxorubicin, and dexamethasone)...He received four cycles of the histone deacetylase inhibitor (HDACi) chidamide combined with COEP chemotherapy (cyclophosphamide, vindesine, etoposide, and prednisone), resulting in a partial remission...Although the prognosis is generally poor, treatment combining HDAC inhibitors such as chidamide with chemotherapy may offer therapeutic potential. Further studies are needed to clarify the molecular mechanisms underlying such lymphoid evolution and to guide optimal management.
    Journal
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TET2 mutation
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • prednisone • Epidaza (chidamide) • vindesine
    7d
    Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov)
    P1/2, N=27, Recruiting, Medical University of South Carolina | Trial completion date: Sep 2027 --> Dec 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells
    7d
    Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma (clinicaltrials.gov)
    P1/2, N=81, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=130 --> 81
    Enrollment closed • Enrollment change
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    7d
    CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Nathan Denlinger | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    7d
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov)
    P2, N=60, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jan 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim)